About Rapid Novor
Rapid Novor is a Healthcare company based in Kitchener (Canada) founded in 2015. Antibody sequencing and discovery services for biopharmaceutical research are provided. Rapid Novor has raised $5 million across 2 funding rounds from investors including Co-win Ventures and Accelerator Centre. The company has 58 employees. Its website rapidnovor.com draws about 37 thousand monthly visits. Rapid Novor offers products and services including Antibody Sequencing, HDX-MS Epitope Mapping, Surface Plasmon Resonance, and Polyclonal Antibody Sequencing. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is Rapid Novor, Inc.
Company details
Provider of antibody sequencing discovery services. These analytical technologies are to be applied to early-stage drug research and development in the biopharmaceutical sector. The company is built around the research of Dr. Ma, a bioinformatician who developed the de novo sequencing tool, Novor. It is claimed that Novor achieved a speed of 300 spectra per second with a MacBook Pro laptop computer, with accuracy better than other available tools. This speed of the analytical software may enable applications that were not possible in the past. Services offered include Antibody Protein Sequencing and Expression.
- Headquarters Kitchener, Canada
- Employees 58
- SectorsHealthcare
- Website rapidnovor.com
- Social LinkedIn X Facebook Instagram
- Legal Name Rapid Novor, Inc.
- Total Equity Funding$5M (USD)
in 2 rounds
- Latest Funding Round$5M (USD), Series A
Jul 2020
- InvestorsCo-win Ventures
& 1 more
- Employee Count58
Products & Services of Rapid Novor
Rapid Novor offers a comprehensive portfolio of products and services, including Antibody Sequencing, HDX-MS Epitope Mapping, Surface Plasmon Resonance, and Polyclonal Antibody Sequencing.
Sequences monoclonal antibodies from protein samples quickly.
Identifies antibody binding sites using mass spectrometry.
Evaluates antibody-antigen interactions with high sensitivity.
Sequences antibodies from blood or mixtures for discovery.
Funding Insights of Rapid Novor
Rapid Novor has successfully raised a total of $5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 2
- Last Round Series A — $5M
- Investors Count 2
All 2 funding rounds of Rapid Novor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $5M | Series A | – | Co-win Ventures | – |
| Jun 2018 | Seed | – | Accelerator Centre | – |
2 investors in total: 2 institutional.
Investors in Rapid Novor
Rapid Novor has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Co-win Ventures and Accelerator Centre.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC fund investing in startups | cowinvc.com | Suzhou, China | ||
Startups are built and accelerated in a structured studio environment. | acceleratorcentre.com | Waterloo, Canada |
Investor details for Rapid Novor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rapid Novor
18 people are tracked at Rapid Novor (7 in leadership, 11 in team); the tracked headcount is 58.
| Name | Role | Group |
|---|---|---|
Mingjie Xie | CEO | Leadership |
Bin Ma | President & Chief Scientist | Leadership |
Thierry Le Bihan | VP Of R&d | Leadership |
Liqiang Yang | Chief Strategy Officer | Leadership |
Qixin Liu | CTO | Leadership |
Iain Rogers | VP, Sales & Marketing | Leadership |
Don Xu | Clinical Lab Director | Leadership |
Marko Jovic | Product Manager | Team |
Jennifer Crha | Regional Sales Manager | Team |
Frank Nemeth | HR Manager | Team |
Kyle Annibale | Scientific Sales Executive | Team |
Genya Gorshtein | Scientific Liaison | Team |
Xiaobing Han | Principal Scientist, External Research Lead, Antibody Discovery | Team |
Yang Liu | Senior Scientific Sales Executive | Team |
Chloé Palesh | Sales Development Representative | Team |
Zac Mcdonald | Senior Scientist & Manager of Proteomics Research | Team |
Teresa Nunez de Villavicencio Diaz | Research Scientist | Team |
Dominic Narang | Manager, HDX Services, Sr. Scientist | Team |
Complete people profiles for Rapid Novor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rapid Novor
3 dated milestones of Rapid Novor across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Rapid Novor is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $5.0M.
Web traffic of Rapid Novor
The website of Rapid Novor (rapidnovor.com) receives about 36.6K visits a month.
- Monthly visits36.6K
▼ 14.5% vs previous month
Websites whose visitors overlap most with Rapid Novor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
abysis.org | abysis.org | 100% | #4,089,004 | – | |
sciencevision.org | sciencevision.org | 99% | #9,526,492 | – | |
biosiva.50webs.org | biosiva.50webs.org | 96% | – | ||
| fiosgenomics.com | 95% | 8.9K | #2,589,391 | View details | |
antibodyresource.com | antibodyresource.com | 92% | #6,501,729 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 30 similar websites and full traffic analytics for Rapid Novor
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 30 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rapid Novor
Complete news archive for Rapid Novor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rapid Novor
Rapid Novor was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Rapid Novor is headquartered in Kitchener, Canada. It is registered at Kitchener, Ontario, Canada.
Rapid Novor is a funded company, having raised a total of $5M across 2 funding rounds to date.
Rapid Novor has 58 employees.
Provider of antibody sequencing discovery services. These analytical technologies are to be applied to early-stage drug research and development in the biopharmaceutical sector. The company is built around the research of Dr. Ma, a bioinformatician who developed the de novo sequencing tool, Novor. It is claimed that Novor achieved a speed of 300 spectra per second with a MacBook Pro laptop computer, with accuracy better than other available tools. This speed of the analytical software may enable applications that were not possible in the past. Services offered include Antibody Protein Sequencing and Expression.
Rapid Novor offers Antibody Sequencing, HDX-MS Epitope Mapping, Surface Plasmon Resonance, and Polyclonal Antibody Sequencing.
Rapid Novor has 2 investors. Key investors include Co-win Ventures, and Accelerator Centre.
Rapid Novor operates through Rapid Novor, Inc..